Lixisenatide: Additional Phase III data

Additional data from the double-blind, international Phase III GETGOAL MONO trial in 361 patients showed that a significantly higher proportion of patients receiving 1- and 2-step titrations

Read the full 278 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE